Skip to main content
SpringerLink
Log in

Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder

Results from the MATRIX Study

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

An Erratum to this article was published on 01 June 2012

Abstract

Background: Overactive bladder syndrome (OAB) is a common condition affecting a significant number of working adults, resulting in increased healthcare utilization, reduced quality of life and decreased work productivity. The MATRIX study was a large, prospective, community-based, observational US study aimed at evaluating the impact of oxybutynin transdermal system (OXY-TDS). In this paper, we report on productivity findings among working adults in MATRIX.

Methods: This study enrolled 2878 adults (aged ≥18 years) with symptoms of OAB from 327 practice sites throughout the US. All subjects received OXY-TDS (3.9 mg/day up to 6 months). Baseline versus end-of-study productivity was measured using the Work Productivity Questionnaire (WPQ). The WPQ includes a subset of questions from the Work Limitations Questionnaire (WLQ) and consists of four scales: (i) physical; (ii) time management; (iii) mental; and (iv) output demands. Overall productivity was measured by the work productivity index score (WPQ Index; a summary score based on scales) and work productivity loss score (WPLS; a measure of reduced output compared with healthy workers). Psychometric performance of the WPQ instrument is also reported, since this study represents the first use of the tool.

Results: Of the participants, 52% were of working age (18–65 years) and 38.6% were employed. A total of 1112 working adults participated in MATRIX and were included in this analysis. They had a mean age of 52.4 years; 92.2% were female and 80.9% were Caucasian. Subjects who reported that they were most affected by OAB were also most impaired at work. After OXY-TDS treatment, participants experienced significant improvements in mean scores for all four WPQ scales (p ≤0.0002) and the mean WPQ Index decreased from 8.2 to 5.5 (p < 0.0001). In addition, the WPLS decreased from 7.7% to 5.2% (p < 0.0001), indicating improvement in work function with OXY-TDS treatment.

Conclusion: OAB contributes to decreased work productivity due to job interruptions as well as fatigue. OXY-TDS may result in productivity improvement when patients receive 3.9 mg/day via twice weekly patch application for up to 6 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Table III
Fig. 3
Table IV
Fig. 4

Similar content being viewed by others

Reference

  1. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study [published erratum appears in BJU Int 2001; 88 (7): 807]. BJU Int 2001; 87 (9): 760–6

    CAS  Google Scholar 

  2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327–36

    PubMed  CAS  Google Scholar 

  3. Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate [letter]. Neurourol Urodyn 2006; 25 (3): 293

    Article  Google Scholar 

  4. Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. BJU Int 2005; 96 (Suppl. 1): 43–5

    Article  PubMed  Google Scholar 

  5. Wu EQ, Birnbaum H, Marynchenko M, et al. Employees with overactive bladder: work loss burden. J Occup Environ Med 2005; 47: 439–46

    Article  PubMed  Google Scholar 

  6. Sand PK, Kelleher C, Pizzi LT, et al. Effect of treatment for overactive bladder on work productivity: results from the MATRIX study [poster]. International Urogynecological Association (IUGA) 31st Annual Meeting; 2006 Sep 6–9; Athens

    Google Scholar 

  7. Milsom I, Irwin DE. A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC study. European Urology 2007; 6 (1): 4–9

    Article  Google Scholar 

  8. Irwin DE, Milsom I, Kopp A, et al. Impact of overactive bladder on symptoms of employment, social interactions and emotional well-being in six European countries. BJU Int 2005; 97: 96–100

    Article  Google Scholar 

  9. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003; 61: 1123–8

    Article  PubMed  Google Scholar 

  10. Grimby A, Milsom I, Molander U, et al. The influence of urinary incontinence on the quality of life of elderly women. Age Ageing 1993; 22: 82–9

    Article  PubMed  CAS  Google Scholar 

  11. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004; 7: 455–63

    Article  PubMed  Google Scholar 

  12. Ko Y, Lin SJ, Salmon JW, et al. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 2005; 11: S103–11

    Google Scholar 

  13. Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial. Am J Obstet Gyn 2006; 195: 1730–5

    Article  Google Scholar 

  14. Hunskaar S, Vinsnes A. The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc 1991; 39: 378–82

    PubMed  CAS  Google Scholar 

  15. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95: 81–5

    Article  PubMed  Google Scholar 

  16. Kelleher CJ, Kreder KJ, Pleil AM, et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S616–30

    Google Scholar 

  17. Kobelt G, Kirchberger I, Malone-Lee J. Review: quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83 (6): 583–90

    Article  PubMed  CAS  Google Scholar 

  18. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005; 23: 263–70

    Article  PubMed  CAS  Google Scholar 

  19. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. Transdermal Oxybutynin Study Group. J Urol 2001; 166: 140–5

    CAS  Google Scholar 

  20. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580–6

    Article  PubMed  CAS  Google Scholar 

  21. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 237–42

    Article  PubMed  Google Scholar 

  22. Talati AR, Pizzi LT, Dahl N, et al. Validation of the work productivity questionnaire: results of the MATRIX study. ISPOR 11th Annual International Meeting; 2006 May 20–24; Philadelphia (PA)

    Google Scholar 

  23. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079–86

    Article  PubMed  Google Scholar 

  24. Kelleher CJ, Reese PR, Pleil AM, et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S608–15

    Google Scholar 

  25. Lerner D, Amick III BC, Rogers WH, et al. The work limitations questionnaire. Med Care 2001; 39: 72–85

    Article  PubMed  CAS  Google Scholar 

  26. Talati AR, Pizzi LT, Dahl N, et al. Work productivity in patients with overactive bladder: results from the MATRIX study. ISPOR 11th Annual International Meeting; 2006 May 20–24; Philadelphia (PA)

    Google Scholar 

  27. Zinner N, Noe L, Rasouliyan L, et al. Impact of solifenacin on resource utilization, work productivity, and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin 2008; 24: 1583–91

    Article  PubMed  CAS  Google Scholar 

  28. Appell RA, Sand PK. Nocturia: etiology, diagnosis, and treatment. Neurourol Urodyn 2008; 27 (1): 34–9

    Article  PubMed  Google Scholar 

  29. Fultz NH, Fisher GG, Jenkins KR. Does urinary incontinence affect middle-aged and older women’s time use and activity patterns? Obstet Gynecol 2004; 104: 1327–34

    Article  PubMed  Google Scholar 

  30. Kopec JA, Esdaile JM. Occupational role performance in persons with back pain. Disabil Rehabil 1998 Oct; 20 (10): 373–9

    Article  PubMed  CAS  Google Scholar 

  31. Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics 2004; 22 (3): 165–84

    Article  PubMed  Google Scholar 

  32. Saha C, Jones MP. Bias in the last observation carried forward method under informative dropout. J Stat Plan Inference 2009; 2 (1): 246–55

    Article  Google Scholar 

  33. Lerner D, Amick BC, Lee JC, et al. Relationship of employee-reported work limitations to work productivity. Med Care 2003; 41 (5): 649–59

    PubMed  Google Scholar 

  34. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007 Apr; 99 (4): 836–44

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by a research grant to Quintiles and Jefferson Medical College from Watson Laboratories, Inc. Jefferson Medical College has in the past, through Laura Pizzi, received honoraria and grants from Watson Laboratories, Inc. Naomi Dahl is an employee of Watson Laboratories, Inc. Peter Sand has acted as a consultant to a number of pharmaceutical companies, including Watson Laboratories, Inc. and Astellas. He has also received honoraria and grants from these companies.

The authors thank Deborah Lerner, PhD, for her guidance regarding adaptation of the Work Limitations Questionnaire for this study. Interim findings were presented in and abstract at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Congress (November 2005), validation findings related to the productivity instrument were presented in an abstract at the ISPOR Annual Meeting (May 2006) and portions of the final results were presented in an abstract at the International Urogynecological Association Annual Meeting (September 2006).

Author information

Authors and Affiliations

  1. Doris N. Grandon Center for Health Economics and Outcomes Research, Jefferson School of Population Health, 1015Walnut Street — Suite 115, Philadelphia, Pennsylvania, 19107, USA

    Laura T. Pizzi & Thomas J. Bunz

  2. Jefferson School of Population Health, Philadelphia, Pennsylvania, USA

    Amy Talati

  3. Quintiles, Falls Church, Virginia, USA

    Eric Gemmen

  4. Watson Laboratories, Inc., Morristown, New Jersey, USA

    Naomi V. Dahl

  5. Evanston Continence Center, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA

    Peter K. Sand

Authors
  1. Laura T. Pizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy Talati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric Gemmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naomi V. Dahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas J. Bunz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter K. Sand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura T. Pizzi.

Additional information

An Erratum for this chapter can be found at http://dx.doi.org/10.2165/11633660-000000000-00000

An erratum to this article is available at http://dx.doi.org/10.2165/11633660-000000000-00000.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pizzi, L.T., Talati, A., Gemmen, E. et al. Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder. Pharmacoeconomics 27, 329–339 (2009). https://doi.org/10.2165/00019053-200927040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200927040-00005

Keywords

Search

Navigation